Cardiogenics Holdings Inc. (CGNH)
OTC PINK OTC PINK Primary Summary
CGNH Chart
Cardiogenics Holdings Inc. (CGNH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cardiogenics Holdings Inc. ever had a stock split?
Cardiogenics Holdings Inc. Profile
| Professional Services Industry | Industrials Sector | Yahia Abdul Gawad CEO | OTC PINK Exchange | 14160X203 CUSIP |
| CA Country | 4 Employees | - Last Dividend | 22 Jun 2010 Last Split | - IPO Date |
Overview
CardioGenics Holdings Inc. specializes in the development and commercialization of innovative diagnostic test products aimed at the in vitro diagnostics testing market globally, including regions such as the United States, Canada, Europe, and beyond. The company has transitioned from its former identity, Jag Media Holdings, Inc., to CardioGenics Holdings Inc. in 2009, signifying a pointed shift towards its current focus on cardiovascular diagnostics. Established in 1997 and headquartered in Mississauga, Canada, CardioGenics has carved a niche in addressing pressing demands for immediate, reliable, and convenient diagnostic solutions for cardiac health management.
Products and Services
CardioGenics Holdings Inc. offers a focused portfolio of diagnostic products and technologies designed to enhance the efficiency and accuracy of cardiac health diagnostics at the point of care and within laboratory settings. These include:
- QL Care Analyzer: This innovative product stands out as a compact, standalone, and automated point-of-care (POC) immunoassay analyzer. It is known for its unique feature of utilizing a proprietary self-metering cartridge, enabling it to conduct immunoassay tests directly at the care point without necessitating extensive lab equipment. The QL Care Analyzer is tailored for rapid deployment and use in various healthcare settings, enabling timely decision-making in critical care situations.
- Immunoassay Tests for Cardiac Markers: CardioGenics has developed a series of immunoassay tests specifically designed to detect cardiac markers present in the blood during a heart attack. These tests are crucial for the swift identification of cardiac events, allowing healthcare providers to administer appropriate treatments in a timely manner, potentially saving lives and reducing the likelihood of long-term cardiac damage.
- Paramagnetic Beads: As part of its offerings to clinical and research laboratories, CardioGenics provides paramagnetic beads. These beads serve as solid surfaces in the performance of heterogeneous immunoassay tests. Their application significantly enhances the precision and reliability of immunoassay procedures, thereby supporting various research and diagnostic activities that require high levels of assay sensitivity and specificity.
